Ingelheim, Germany

Hagen Graebner



 

Average Co-Inventor Count = 4.6

ph-index = 1

Forward Citations = 39(Granted Patents)


Company Filing History:


Years Active: 2007-2015

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations by Hagen Graebner

Introduction

Hagen Graebner is a notable inventor based in Ingelheim, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of micronized forms of medicinal compounds. With a total of 3 patents to his name, Graebner's work is recognized for its potential impact on medication efficacy.

Latest Patents

Hagen Graebner's latest patents include a method for producing a micronized, virtually anhydrous form of a specific compound, which is crucial for creating effective medicaments with anticholinergic effects. Another significant patent involves a crystalline micronisate of the same compound, detailing processes for its manufacture and its application in pharmaceutical compositions. These innovations highlight his focus on enhancing drug formulations for better therapeutic outcomes.

Career Highlights

Graebner is currently associated with Boehringer Ingelheim Pharma GmbH & Co. KG, a leading company in the pharmaceutical industry. His work at this esteemed organization has allowed him to push the boundaries of pharmaceutical science, contributing to advancements that can improve patient care.

Collaborations

Throughout his career, Hagen Graebner has collaborated with notable colleagues, including Michael Trunk and Michael Walz. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Hagen Graebner's contributions to the field of pharmaceuticals through his innovative patents demonstrate his commitment to improving medication formulations. His work continues to influence the development of effective therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…